文献速递烧伤创面修复

烧伤患者静脉血栓栓塞症药物预防:文献综述与单中心经验

Venous Thromboembolism Chemoprophylaxis in Burn Patients: A Literature Review and Single-Institution Experience.
PubMed 文献 · J Burn Care Res · 2021-01-01

烧伤住院患者符合Virchow三联征,易发生静脉血栓栓塞症(VTE)。本文按PRISMA指南系统综述烧伤患者VTE药物预防研究,并回顾性分析本烧伤中心2015年6月至2019年6月收治患者资料。文献报告VTE发生率范围0.25%至47.1%,本中心采用5000U普通肝素皮下注射每8小时方案,VTE总发生率1.03%。

要点

  • 烧伤患者因内皮损伤、高凝和淤滞易发生VTE。
  • 文献VTE发生率差异大(0.25%–47.1%),缺乏统一预防方案。
  • 本中心5000U普通肝素每8小时方案VTE发生率1.03%。

核心结论

  • 文献报告的烧伤患者VTE发生率范围宽泛,难以准确反映任一药物预防方案的效果。
  • 本中心采用单一、安全且经济的普通肝素方案,VTE发生率低,与大型全国性回顾研究相当。

研究设计与样本

  • 按PRISMA指南进行系统综述,纳入38项关于烧伤患者VTE药物预防的研究。
  • 回顾性分析2015年6月至2019年6月美国烧伤协会认证烧伤中心收治的1068例患者资料。

主要发现

  • 12项报告VTE发生率的研究中,发生率范围为0.25%至47.1%。
  • 两项最大回顾性研究(n=33637和n=36638)报告VTE发生率分别为0.61%和0.8%。
  • 本中心1068例患者中,深静脉血栓(DVT)9例(0.84%),肺栓塞(PE)2例(0.19%),总VTE发生率1.03%。
  • 仅1例发生肝素诱导的血小板减少症(HIT),未观察到其他肝素相关并发症。

关键数值与推荐

  • 本中心高危患者接受普通肝素5000U皮下注射每8小时一次,不进行常规监测以控制成本。
  • 文献中预防方案多样,但可见基于血清抗Xa因子水平调整低分子肝素皮下剂量的趋势。

临床怎么用

  • 烧伤患者应考虑VTE药物预防,本中心方案可作为安全、经济的选择。
  • 采用普通肝素5000U每8小时方案无需常规监测,VTE发生率低且HIT罕见。

局限性

  • 文献报告的VTE发生率不可靠,难以评估单一预防方案的效果。
  • 本中心经验为单中心回顾性研究,结论需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hospitalized burn patients meet the criteria for Virchow's triad (endothelial damage, hypercoagulability, and stasis), predisposing them to venous thromboembolism (VTE). Although the disease burden of VTE suggests a need for prevention in this population, unreliable reported VTE rates, costly and complicated prophylaxis regimens, and chemoprophylaxis risks have prevented the establishment of a universal protocol. This paper reviews thromboprophylaxis practices both in the literature and at our own institution. A systematic review was conducted according to PRISMA guidelines identifying studies pertaining to VTE chemoprophylaxis in burn patients. Additionally, medical records of patients admitted to an American Burn Association-verified burn center between June 2015 and June 2019 were retrospectively reviewed for demographics, chemoprophylaxis, and presence of VTE defined as either deep vein thrombosis (DVT) or pulmonary embolism (PE). Thirty-eight studies met inclusion criteria. In the 12 studies that reported VTE incidence, rates ranged widely from 0.25% to 47.1%. The two largest retrospective studies (n = 33,637 and 36,638) reported a VTE incidence of 0.61% and 0.8% in populations with unknown or inconsistently recorded chemoprophylaxis. Throughout the literature, prevention protocols were mixed, though a trend toward using dose-adjusted subcutaneous low molecular weight heparin based on serum anti-factor Xa level was noted. At our burn center, 1,068 patients met study criteria. At-risk patients received a simple chemoprophylaxis regimen of 5000U of subcutaneous unfractionated heparin every 8 hours. No routine monitoring tests were performed to limit cost. Nine cases of DVT and two cases of PE were identified with an incidence of 0.84% and 0.19%, respectively, and a total VTE incidence of 1.03%. Only one patient developed heparin-induced thrombocytopenia (HIT). No cases of other heparin-associated complications were observed. VTE incidence rates reported in the literature are wide-ranging and poorly capture the effect of any one chemoprophylaxis regimen in the burn population. Our center uses a single, safe, and cost-effective protocol effecting a low VTE rate comparable to that of large national retrospective studies.

来源:J Burn Care Res,查看原文。版权归原作者所有。

引用

  1. Liu A, Minasian RA, Maniago E, et al. Venous Thromboembolism Chemoprophylaxis in Burn Patients: A Literature Review and Single-Institution Experience. J Burn Care Res. 2021. PMID: 32842151. doi:10.1093/jbcr/iraa143

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。